By contrast, associations of stronger upregulation of SIRT1, SIRT2, and SIRT5 with sensitivity to dasatinib were unexpected, since previous studies had reported benefits of their downregulation or depletion in improving cancer outcomes [13,14,78,79]. This evidence concerns the gene SIRT2 and cancer.